Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 22, 2022, titled "Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets".
Press Release Dec 22 2022
Filed with NSE ·
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 10 2022
- Press Release Dec 02 2022
- Press Release Dec 01 2022
- Press Release Nov 28 2022
- Press Release Nov 23 2022
Later from Zydus Lifesciences
- Loss of Share Certificates
- Press Release Dec 30 2022
- Press Release Jan 06 2023
- Press Release Jan 10 2023
- Zydus Lifesciences Limited Press Release Jan 12 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences